دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Epidemiology and treatment of acute and chronic heart failure
Filippo Crea
doi : 10.1093/eurheartj/ehad022
European Heart Journal, Volume 44, Issue 5, 1 February 2023, Pages 329–332
Prevention of nuclear war: a call to action for cardiovascular professionals
James Muller, Patrick Serruys, Niel Grubb, John Pastore
doi : 10.1093/eurheartj/ehac702
European Heart Journal, Volume 44, Issue 5, 1 February 2023, Pages 333–335
The ‘10 commandments’ for the 2022 European Society of Cardiology guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
Julinda Mehilli, Sigrun Halvorsen
doi : 10.1093/eurheartj/ehac703
European Heart Journal, Volume 44, Issue 5, 1 February 2023, Pages 336–337
In memoriam: Professor Domenico Pagano
Mario Gaudino, Nick Freemantle, Rafael Sadaba
doi : 10.1093/eurheartj/ehac725
European Heart Journal, Volume 44, Issue 5, 1 February 2023, Pages 338–339
A gender issue in the diagnostic imaging work-up of stable coronary artery disease? Insights from DISCHARGE
Rocco Vergallo, Massimo Volpe
doi : 10.1093/eurheartj/ehac720
European Heart Journal, Volume 44, Issue 5, 1 February 2023, Pages 340–341
The year in cardiovascular medicine 2022: the top 10 papers in heart failure and cardiomyopathies
Rudolf A de Boer, Johann Bauersachs
doi : 10.1093/eurheartj/ehac781
European Heart Journal, Volume 44, Issue 5, 1 February 2023, Pages 342–344
The year in cardiovascular medicine 2022: the top 10 papers in arrhythmias
Pier D Lambiase, Prashantan Sanders, Harry J G M Crijns
doi : 10.1093/eurheartj/ehac753
European Heart Journal, Volume 44, Issue 5, 1 February 2023, Pages 345–347
The year in cardiovascular medicine 2022: the top 10 papers in cardio-oncology
Joerg Herrmann, Teresa Lpez-Fernandez, Alexander R Lyon
doi : 10.1093/eurheartj/ehac813
European Heart Journal, Volume 44, Issue 5, 1 February 2023, Pages 348–350,
Surgical or percutaneous coronary revascularization for heart failure: an in silico model using routinely collected health data to emulate a clinical trial
Suraj Pathak, Florence Y Lai, Joanne Miksza, Mark C Petrie, Marius Roman, Sarah Murray, Jeremy Dearling, Divaka Perera, Gavin J Murphy
doi : 10.1093/eurheartj/ehac670
European Heart Journal, Volume 44, Issue 5, 1 February 2023, Pages 351–364
The choice of revascularization with coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) in people with ischaemic left ventricular dysfunction is not guided by high-quality evidence.
Revascularization in ischaemic cardiomyopathy: how to interpret current evidence
Bernard J Gersh, David De Mets
doi : 10.1093/eurheartj/ehac794
European Heart Journal, Volume 44, Issue 5, 1 February 2023, Pages 365–367
Albuminuria as a marker of systemic congestion in patients with heart failure
Eva M Boorsma, Jozine M ter Maaten, Kevin Damman, Bart J van Essen, Faiez Zannad, Dirk J van Veldhuisen, Nilesh J Samani, Kenneth Dickstein, Marco Metra, Gerasimos Filippatos, Chim C Lang, Leong Ng, Stefan D Anker, John G Cleland, Pierpaolo Pellicori, Ron T Gansevoort, Hiddo J L Heerspink, Adriaan A Voors, Johanna E Emmens
doi : 10.1093/eurheartj/ehac528
European Heart Journal, Volume 44, Issue 5, 1 February 2023, Pages 368–380
Albuminuria is common in patients with heart failure and associated with worse outcomes. The underlying pathophysiological mechanism of albuminuria in heart failure is still incompletely understood. The association of clinical characteristics and biomarker profile with albuminuria in patients with heart failure with both reduced and preserved ejection fractions were evaluated.
Rethinking albuminuria as a marker to drive treatment in congestive heart failure
Nicola Riccardo Pugliese, Stefano Masi, Stefano Taddei
doi : 10.1093/eurheartj/ehac612
European Heart Journal, Volume 44, Issue 5, 1 February 2023, Pages 381–382
Epidemiology of heart failure in young adults: a French nationwide cohort study
Emmanuel Lecoeur, Orianne Domengé, Antoine Fayol, Anne-Sophie Jannot, Jean-Sébastien Hulot
doi : 10.1093/eurheartj/ehac651
European Heart Journal, Volume 44, Issue 5, 1 February 2023, Pages 383–392
Heart failure (HF) in young adults is uncommon, and changes in its incidence and prognosis in recent years are poorly described.
Increasing incidence of heart failure among young adults: how can we stop it?
Maria Schaufelberger, Carmen Basic
doi : 10.1093/eurheartj/ehac730
European Heart Journal, Volume 44, Issue 5, 1 February 2023, Pages 393–395
Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
Michael Böhm, Stefan Anker, Felix Mahfoud, Lucas Lauder, Gerasimos Filippatos, João Pedro Ferreira, Stuart J Pocock, Martina Brueckmann, Ilias Saloustros, Elke Schüler, Christoph Wanner, Faiez Zannad, Milton Packer, Javed Butler
doi : 10.1093/eurheartj/ehac693
European Heart Journal, Volume 44, Issue 5, 1 February 2023, Pages 396–407
Empagliflozin reduces the risk of cardiovascular death or heart failure (HF) hospitalization in patients with HF and preserved ejection fraction. This study aims to evaluate if systolic blood pressure (SBP) moderates these effects.
A welcome ‘failure’ of gliflozins: blood pressure reduction in heart failure
Kieran F Docherty, Pardeep S Jhund
doi : 10.1093/eurheartj/ehac712
European Heart Journal, Volume 44, Issue 5, 1 February 2023, Pages 408–410
Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial
Joan Carles Trullà s, José Luis Morales-Rull, Jesús Casado, Margarita Carrera-Izquierdo, Marta Sánchez-Marteles, Alicia Conde-Martel, Melitón Francisco Dávila-Ramos, Pau Llácer, Prado Salamanca-Bautista, José Pérez-Silvestre, Miguel Ã�ngel PlasÃn, José Manuel Cerqueiro, Paloma Gil, Francesc Formiga, Luis Manzano, CLOROTIC trial investigators
doi : 10.1093/eurheartj/ehac689
European Heart Journal, Volume 44, Issue 5, 1 February 2023, Pages 411–421
To evaluate whether the addition of hydrochlorothiazide (HCTZ) to intravenous furosemide is a safe and effective strategy for improving diuretic response in acute heart failure (AHF).
Time to revisit combination loop and thiazide diuretic therapy for patients with acute heart failure
Rosita Zakeri, David G Wilson, Selma F Mohammed
doi : 10.1093/eurheartj/ehac784
European Heart Journal, Volume 44, Issue 5, 1 February 2023, Pages 422–424
Left atrial volume and left ventricular mass for pulmonary capillary wedge pressure assessment with cardiovascular magnetic resonance: accurate enough for clinical use?
Davide Genovese, Luigi P Badano, Martina Perazzolo Marra
doi : 10.1093/eurheartj/ehac739
European Heart Journal, Volume 44, Issue 5, 1 February 2023, Pages 425–426
Cardiovascular magnetic resonance can improve the precision for left ventricular filling pressure assessment
Rebecca Gosling, Andrew J Swift, Pankaj Garg
doi : 10.1093/eurheartj/ehac740
European Heart Journal, Volume 44, Issue 5, 1 February 2023, Pages 427–428
Cantrell syndrome
Leizhi Ku, Xiaojing Ma
doi : 10.1093/eurheartj/ehac563
European Heart Journal, Volume 44, Issue 5, 1 February 2023, Page 429
Resection of an obstructive chiari network via a minimally invasive approach
Zhuheng Wu, Zedong He, Lin Xie, Yajiao Li, Changping Gan
doi : 10.1093/eurheartj/ehac687
European Heart Journal, Volume 44, Issue 5, 1 February 2023, Page 430
Corrigendum to: HFp2EF: heart failure with pulmonary dysfunction and preserved ejection fraction?
doi : 10.1093/eurheartj/ehac766
European Heart Journal, Volume 44, Issue 5, 1 February 2023, Page 380
Erratum to: The ‘10 commandments’ for the 2022 European Society of Cardiology guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
doi : 10.1093/eurheartj/ehac815
European Heart Journal, Volume 44, Issue 5, 1 February 2023, Page 392
